268 related articles for article (PubMed ID: 22730470)
1. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
Shaheen NJ; Denison H; Björck K; Karlsson M; Silberg DG
Gut; 2013 Sep; 62(9):1248-55. PubMed ID: 22730470
[TBL] [Abstract][Full Text] [Related]
2. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
Boeckxstaens GE; Beaumont H; Hatlebakk JG; Silberg DG; Björck K; Karlsson M; Denison H
Gut; 2011 Sep; 60(9):1182-8. PubMed ID: 21402616
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.
Miner PB; Silberg DG; Ruth M; Miller F; Pandolfino J
BMC Gastroenterol; 2014 Nov; 14():188. PubMed ID: 25407279
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
Vakil NB; Huff FJ; Cundy KC
Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
[TBL] [Abstract][Full Text] [Related]
5. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease.
Boeckxstaens GE; Beaumont H; Mertens V; Denison H; Ruth M; Adler J; Silberg DG; Sifrim D
Gastroenterology; 2010 Aug; 139(2):409-17. PubMed ID: 20451523
[TBL] [Abstract][Full Text] [Related]
6. Lesogaberan, a GABA(B) agonist for the potential treatment of gastroesophageal reflux disease.
Bredenoord AJ
IDrugs; 2009 Sep; 12(9):576-84. PubMed ID: 19697277
[TBL] [Abstract][Full Text] [Related]
7. Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy.
Shaheen NJ; Denison H; Björck K; Silberg DG
Am J Gastroenterol; 2013 Apr; 108(4):529-34. PubMed ID: 23318482
[TBL] [Abstract][Full Text] [Related]
8. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects.
Boeckxstaens GE; Rydholm H; Lei A; Adler J; Ruth M
Aliment Pharmacol Ther; 2010 Jun; 31(11):1208-17. PubMed ID: 20222915
[TBL] [Abstract][Full Text] [Related]
9. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
Beaumont H; Boeckxstaens GE
Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
[TBL] [Abstract][Full Text] [Related]
10. The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs.
Brändén L; Fredriksson A; Harring E; Jensen J; Lehmann A
Eur J Pharmacol; 2010 May; 634(1-3):138-41. PubMed ID: 20176012
[TBL] [Abstract][Full Text] [Related]
11. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.
Boeckxstaens GE; Denison H; Jensen JM; Lehmann A; Ruth M
Curr Opin Pharmacol; 2011 Dec; 11(6):630-3. PubMed ID: 22036168
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.
Niazi M; Silberg DG; Miller F; Ruth M; Holmberg AA
Drugs R D; 2010; 10(4):243-51. PubMed ID: 21171670
[TBL] [Abstract][Full Text] [Related]
13. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
[TBL] [Abstract][Full Text] [Related]
14. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: a novel GABA(B)-receptor agonist reflux inhibitor.
Niazi M; Skrtic S; Ruth M; Holmberg AA
Drugs R D; 2011; 11(1):77-83. PubMed ID: 21410297
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field?
Falk GW
Gastroenterology; 2010 Aug; 139(2):377-9. PubMed ID: 20600061
[No Abstract] [Full Text] [Related]
17. Novel treatments of GERD: focus on the lower esophageal sphincter.
Lehmann A
Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():103-10. PubMed ID: 18924449
[TBL] [Abstract][Full Text] [Related]
18. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
19. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study.
Moawad FJ; Betteridge JD; Boger JA; Cheng FK; Belle LS; Chen YJ; Maydonovitch CL; Wong RK
Aliment Pharmacol Ther; 2013 May; 37(10):1011-8. PubMed ID: 23560727
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy.
Shaheen NJ; Adler J; Dedrie S; Johnson D; Malfertheiner P; Miner P; Meulemans A; Poole L; Tack J; Thielemans L; Troy S; Vakil N; Zerbib F; Ruth M
Aliment Pharmacol Ther; 2015 Apr; 41(7):649-61. PubMed ID: 25693609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
